GeoVax Reveals Promising Dual-Action Vaccine with Potential COVID-19 and Mpox Protection
A novel vaccine candidate, GEO-CM04S1, demonstrates robust immunogenicity against both COVID-19 and Mpox in immunocompromised and healthy populations, offering potential breakthrough in infectious disease prevention.
Biotechnology company GeoVax Labs has revealed promising clinical data for its multi-antigen vaccine GEO-CM04S1, showing potential to protect against both COVID-19 and Mpox. Presented at the American Association of Immunologists Annual Meeting, the research highlights the vaccine's unique ability to generate strong immune responses in vulnerable patient populations.
The study, conducted with City of Hope Medical Center, demonstrated robust and durable anti-SARS-CoV-2 immune responses in blood cancer and cell transplant patients. Notably, the vaccine showed cross-reactive immunity against COVID-19 variants like Omicron XBB.1.5 and generated comparable immune responses to the current licensed smallpox/Mpox vaccine.
What sets GEO-CM04S1 apart is its potential to provide dual protection. Researchers found that sera from vaccinated healthy adults and non-human primates showed cross-reactive immunity against Mpox virus, with protective effects demonstrated in susceptible mice challenged with the virus.
Dr. Kelly T. McKee, GeoVax's Chief Medical Officer, emphasized the significance of the vaccine's broad immunity, particularly for immunocompromised individuals and regions where Mpox is endemic. The vaccine's design, using a synthetic Modified Vaccinia Ankara vector, allows it to express both spike and nucleocapsid antigens of SARS-CoV-2.
Currently, GEO-CM04S1 is being evaluated in three Phase 2 clinical trials, exploring its effectiveness as a primary vaccine for immunocompromised patients, a booster for chronic lymphocytic leukemia patients, and a booster for healthy adults previously vaccinated with mRNA COVID-19 vaccines.
These findings represent a potential significant advancement in vaccine technology, offering hope for more comprehensive protection against evolving infectious diseases.